Image 1 of 2▼

In this Friday, April 26, 2019 photo, a box of RELPAX migraine pills manufactured by Pfizer are arranged for a photo in Doral, Fla. Pfizer Inc. reports financial results Tuesday, April 30. (AP Photo/Wilfredo Lee)

Higher prescription drugs sales and restrained spending together gave drugmaker Pfizer a 9% jump in first quarter profit as it easily topped analysts' profit expectations.

Continue Reading Below

The maker of blood thinner Eliquis and Xeljanz for rheumatoid arthritis saw their sales each jump by 30% or more, lifting prescription drug sales by 3 percent. Sales of Pfizer's off-patent drugs and its consumer health products both dipped, though.

The New York drugmaker on Tuesday reported earnings of $3.88 billion, or 68 cents per share. Earnings, adjusted for non-recurring costs, were 85 cents per share, far exceeding projections of 77 cents from Wall Street analysts, according to a survey by Zacks Investment Research.

The biggest U.S. drugmaker by revenue posted sales of $13.12 billion, up from $12.91 billion in 2018's first quarter.

Pfizer raised its full-year profit forecast by a penny, to a range of $2.83 to $2.93 per share. It reaffirmed the sales forecast it gave in January, for a range of $52 billion to $54 billion.

Pfizer shares were moving higher before the opening bell.


Portions of this story were generated by Automated Insights using data from Zacks Investment Research. Access a Zacks stock report on PFE at

Source Link: